covid-19-associated mucormycosis, CAM, antifungal therapy, individual participant data meta analysis, opportunistic infections, corticosteroids use in CAM, fatality in CAM, mucormycosis, corticosteroid use, fungal infections
Immune checkpoint inhibitors, FDA adverse event reporting system (FAERS), Cutaneous adverse reactions, Immunotherapy, Severe cutaneous adverse reactions (SCAR), Skin toxicity, Dermatologic complications